Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More
Xconomy
OCTOBER 7, 2016
PRICE FIGHTS. —The Institute for Clinical and Economic Review (ICER), whose drug-value analyses set the pharma industry’s teeth on edge , issued a new report on PD-1 inhibitors , part of the first wave of cancer immunotherapy drugs to be approved. With some caveats, ICER recommended lower prices. CLINICAL NEWS.
Let's personalize your content